Short answer
Allogene Therapeutics, Inc. (ALLO) filed its Q3 2026 10-Q quarterly report on Nov 6, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$50M.
Q3 2026 key financials · XBRL
- Revenue
- $0
- −100.0% QoQ
- Net income
- −$50M
- −21.7% YoY · −18.0% QoQ
- EPS (diluted)
- −$0.14
- +26.3% YoY · −16.7% QoQ
Source: XBRL data from the Allogene Therapeutics, Inc. (ALLO) Q3 2026 10-Q on SEC EDGAR. USD.
Allogene Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0, versus $0 YoY, with revenue generated exclusively from Overland licensing
- Net loss $50.4M, versus $41.4M YoY, operating expenses $54.8M versus $44.9M
- Research and development $41.9M, up $10.8M YoY, driven by cema-cel development and manufacturing reactivation
- Cash, equivalents and investments $388.9M, runway into Q1 2029, operating cash use $81.0M year to date
- Capital deployment: $187.9M April offering proceeds and $20.7M ATM proceeds, ALPHA3 enrollment expected complete by end-2027
Risk Factors
- Newly added risk: CFO retirement effective November 6, 2026, alongside CEO transition and interim CMO role
- Most material update: FCA arm discontinued after Grade 5 SAE, with continued patient follow-up potentially triggering regulatory actions
- Regulatory risk: EU GDPR breaches could incur fines up to €20,000,000 or 4% of annual total revenue
- Near-term clinical risk: ALPHA3 enrollment delays from anticipated high MRD screen-failure rates
- Financial risk: $388.9 million in cash and investments as of September 30, 2026, with substantial additional financing required
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Allogene Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.